Exenatide, a synthetic GLP-1 receptor agonist, was acutely administered to eight male subjects with suboptimally controlled non-insulin-treated T2DM and without CAD in order to evaluate myocardial glucose uptake and MBF using PET during a pituitary-pancreatic hyperglycemic clamp with 18F-fluorodeoxyglucose and 13N-ammonia as tracers. The gene discussed is GLP1R; the disease is coronary artery disorder.